Search Results

Royal Philips Commences DEFINE GPS Study

June 22, 2021—Royal Philips announced the commencement of the DEFINE GPS study with the first patient enrolled by Allen Jeremias, MD, at St. Francis Hospital in Roslyn, New York.

CathWorks FFRangio System’s ALL-RISE Trial Completes Enrollment

January 6, 2025—CathWorks recently announced the completion of enrollment for the ALL-RISE randomized controlled trial, evaluating the clinical and economic benefits of the CathWorks FFRangio system in diagnosing and treating coronary artery disease.

Orchestra BioMed’s Pivotal Trial of Virtue SAB for Coronary ISR Begins Enrollment

November 10, 2025—Orchestra BioMed Holdings, Inc. announced that the first patients were enrolled in the United States investigational device exemption (IDE) pivotal study for the company’s Virtue sirolimus angioinfusion balloon (Virtue SAB) in the treatment of coronary in-stent restenosis (ISR).

Philips’ DEFINE GPS Trial Will Assess Outcomes of PCI Guided by an Integrated Platform of iFR and Angiogram

February 11, 2020—Royal Philips announced a new randomized controlled trial to assess patient outcomes after receiving percutaneous coronary intervention (PCI) guided by Philips’ coregistration platform (which combines data of instant wave-free ratio (iFR) measurement and angiography) compared with the standard of care treatment guided by angiography alone.

Neovasc’s COSIRA-II Pivotal Trial of Reducer Device Begins Enrollment

January 5, 2022—Neovasc Inc. announced enrollment of the first patient in the pivotal COSIRA-II clinical trial of the company’s coronary sinus Reducer device for the treatment of refractory angina.

DEFINE PCI Study Assesses Philips' iFR Guidance Technology

March 17, 2019—Royal Philips announced that results of the DEFINE PCI study, which assessed the level of residual ischemia found in patients after percutaneous coronary interventions (PCI), were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session, being held March 16–18 in New Orleans, Louisiana.

1-Year DEFINE PCI Data Presented for Philips' iFR-Guided Interventions

October 15, 2020—Royal Philips announced that the 1-year results of the DEFINE PCI study were presented at TCT Connect, the 32nd annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation held online October 14-18, 2020.

First Patient Enrolled in CathWorks ALL-RISE Study Evaluating FFRangio System

June 28, 2023—CathWorks announced that the first patient has been enrolled in the ALL-RISE study sponsored by the company.